THE DISCOVERY, FINANCING AND EVALUATION OF GENOMIC MEDICINE: IMPLICATIONS FOR THE COMPARATIVE EFFECTIVENESS OF CANCER CARE

This symposium features leading experts in genomic medicine applied to cancer drawn from different disciplines: clinical discovery, trial design, economics, safety and efficacy assessments and comparative effectiveness research. Through formal comments and moderated group discussion, we aim to provide the SMDM audience an introduction to the emerging role each of these disciplines play in the design, implementation and use by decision makers of future comparative effectiveness research on genomic medicines. We will explore the importance of scientific evidence complemented by patient, family and provider perspectives on the practical implications of genomic medicine.

Speakers:
J. Jack Lee, PhD, will discuss adaptive clinical trial design in "personalized" cancer trials.

Tomas J. Philipson, PhD, will discuss the incentives for research and development of personalized medicines from a private pharmaceutical firm's perspective, FDA regulatory assessments, reimbursement and coverage decision making for personalized medicines.

Mark J. Ratain, MD, will discuss drug discovery, establishing the clinical value of personalized medicine, adoption of new tests and medicines from a physician's perspective.